PARADIGM BIOCAPITAL ADVISORS LP
Q1 2026 Form 13-F
NEW YORK, NEW YORK
CIK 0001855655
· CRD 312544
· SEC-registered investment adviser
$4.9B Reported Value Total
PARADIGM BIOCAPITAL ADVISORS LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $4,469,161,523, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $4.1B gross asset value
Hedge Fund: $4.1B
Source: Form ADV filed 2026-08-27
Reported value
$4.9B
Quarter over quarter
+15.8%
Holdings
35
Top-10 concentration
67.7%
Key People
Form ADV owners & control persons
Dr. Senai Nmn Asefaw
CHIEF INVESTMENT OFFICER / LIMITED PARTNER
David Kyungtaek Kim
CHIEF OPERATING OFFICER / CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 15, 2026 |
| Form | 13F-HR |
| Reported value | $4.9B |
| Positions | 35 |
| Change in reported value | +24.9% |
| New positions | 10 |
| Exited positions | 4 |
| Position turnover | 35.9% |
| Top-10 concentration | 67.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
28 | $5.3B |
|
Q1 2026 13F
Filed May 15, 2026
|
35 | $4.9B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
29 | $3.9B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
33 | $3.5B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
28 | $2.3B |
|
Q1 2025 13F
Filed May 15, 2025
|
27 | $2.2B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
28 | $2.9B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
31 | $3.0B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
35 | $2.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
34 | $2.8B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
29 | $2.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
29 | $1.5B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
29 | $1.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
25 | $1.1B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
23 | $851.9M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
27 | $750.1M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
23 | $501.5M |
|
Q1 2022 13F
Filed May 16, 2022
|
25 | $378.2M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
24 | $350.2M |
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ACLX ARCELLX INC | $663.0M | 13.55% |
| 2 | RVMD REVOLUTION MEDICINES INC | $647.3M | 13.23% |
| 3 | NUVL NUVALENT INC | $545.5M | 11.15% |
| 4 | PCVX VAXCYTE INC | $278.5M | 5.69% |
| 5 | EWTX EDGEWISE THERAPEUTICS INC | $232.0M | 4.74% |
| 6 | GMAB GENMAB A/S | $213.8M | 4.37% |
| 7 | INSM INSMED INC | $205.1M | 4.19% |
| 8 | TARS TARSUS PHARMACEUTICALS INC | $179.7M | 3.67% |
| 9 | BLTE BELITE BIO INC | $177.7M | 3.63% |
| 10 | ERAS ERASCA INC | $168.2M | 3.44% |
| 11 | CNTA CENTESSA PHARMACEUTICALS PLC | $142.0M | 2.9% |
| 12 | OLMA OLEMA PHARMACEUTICALS INC | $119.6M | 2.44% |
| 13 | TERN TERNS PHARMACEUTICALS INC | $116.9M | 2.39% |
| 14 | ORKA ORUKA THERAPEUTICS INC | $113.8M | 2.33% |
| 15 | APGE APOGEE THERAPEUTICS INC | $113.5M | 2.32% |
| 16 | SYRE SPYRE THERAPEUTICS INC | $98.7M | 2.02% |
| 17 | CYTK CYTOKINETICS INC | $97.6M | 1.99% |
| 18 | ABVX ABIVAX SA | $86.0M | 1.76% |
| 19 | TNGX TANGO THERAPEUTICS INC | $83.9M | 1.71% |
| 20 | MAZE MAZE THERAPEUTICS INC | $81.9M | 1.67% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.